Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Caelyx monotherapy in advanced mycosis fungoides
2004-003728-36Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2005
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF), sponsored by European Organisation for Research and Treatment of Cancer. Started Aug 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on 2004-003728-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003728-36.